7 Pharmaceuticals Stocks to Buy Now

7 Pharmaceuticals Stocks to Buy Now

7 Pharmaceuticals stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Taro Pharmaceutical Industries Ltd. (TARO) boosts its rating from a C to a B this week. Taro Pharmaceutical Industries Ltd. is engaged in developing, manufacturing, and marketing prescription and over-the-counter pharmaceutical products, as well as active pharmaceutical ingredients in the United States, Canada and Israel. The company also gets A’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TARO stock.

Johnson & Johnson (JNJ) gets a higher grade this week, advancing from a B last week to a A. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of JNJ stock.

Aerie Pharmaceuticals, Inc. (AERI) improves from a C to a B rating this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of AERI stock.

Nektar Therapeutics (NKTR) earns a A this week, jumping up from last week’s grade of B. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of NKTR stock.

Auris Medical Holding AG (EARS) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EARS stock.

This week, Ampio Pharmaceuticals, Inc. (AMPE) pushes up from a C to a A rating. Ampio Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of AMPE stock.

Repros Therapeutics Inc. (RPRX) shows solid improvement this week. The company’s rating rises from a C to a B. Repros Therapeutics Inc. is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of RPRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/04/7-pharmaceuticals-stocks-to-buy-now-3/.

©2019 InvestorPlace Media, LLC